Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer
Kyoichi Kaira Nobuyuki Yamamoto Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan notyethaveacquiredasecondarymutationinpatientswho havebeenreceivinggefitinibforlessthan12months.Haraet al. [6] describedthathigherefficacyoferlotinibaftergefitinib canachievedwithoptimalpatientselectionbasedonthefollowing criteria: good performance status, benefit from prior gefitinib therapy, and insertion cytotoxic chemotherapies betweengefitinibanderlotinib.Intheirstudy,11outof125 patientshadaPRand44patientshadSD,yieldinganoverall responserateof9%andaDCof44%.However,32patients with these optimal selection criteria had a response rate of 25%andaDCof72%.Wongetal. [7] reportedontheefficacy as salvage treatment after failure of first-line gefitinib in NSCLC, and 18 (85.7%) out of 21 patients had DC with gefitinib and 12 (57.1%) patients with salvage erlotinib, demonstrating a significant association between DC with gefitinib and erlotinib (p = 0.031). They concluded that erlotinibwaseffectiveinNSCLCpatientswhohadpriorDC with first-line gefitinib. Song et al. [8] had documented that patients with without EGFR mutation can probably benefit from erlotinibtreatmentaftergefitinibfailure.Theresultsof thesestudiessuggestthattheefficacyoferlotinibafterfailure of gefitinibiscorrelatedwithanybenefitfrompriorgefitinib treatment, however the mechanisms have not been completelyclarified.
Recently,Jackmanetal. [9] proposedthefollowingcriteria for acquired resistance to EGFR-TKIs in NSCLC: (i) previous treatment with a single-agent EGFR-TKI; (ii) both or eitherofthefollowing:(a)atumorharboringanEGFRmutation known to be related to drug sensitivity or (b) objective clinicalbenefitbyEGFR-TKI(PRorcompleteresponse,or significant(6months)clinicalbenefit(SD)afterinitiationof EGFR-TKIs); (iii) disease progression while on continuous treatmentwithEGFR-TKIswithinthelast30days;and(iv) nointerveningtherapybetweencessationofEGFR-TKIsand initiationofnewtherapy.TheNSCLCpatientswithlong-term SDofmorethan6monthswhilereceivinggefitinibalsomet thesecriteria,however,subsequentEGFR-TKItreatmenthas beenreportedtoachieveclinicalbenefit.12studiesregarding
Saito et al. [1] have documented in this issue of Onkologie that erlotinib is one of the therapeutic options for patients withadvancednon-smallcelllungcancer(NSCLC)withlongterm stable disease (SD) of more than 6 months who had previously been on gefitinib. In their study, 21 patients with NSCLCwereretrospectivelyevaluated,9%achievedapartial response (PR) and 36% disease control (DC). The median survivaltime(MST)ofpatientswithDCwas369days,which was longer than in previous reports [2] . Their preliminary datasuggestthaterlotinibcanproduceclinicalbenefitinpatientswithlong-termSDofmorethan6monthsongefitinib treatment.
Recently,wedescribedthepooledanalysisof11published articles(106patients)onerlotinibafterfailureofgefitinib [2] . Witherlotinibtherapy,PRwasobservedin9.9%andDCin 29.2%ofpatients,correspondingtotheresultsofSato'sstudy [1] .Choetal. [3] alsoconcludedthaterlotinibseemstobea potential therapeutic option for the treatment of advanced NSCLCpatientswhoshowSDwhilereceivinggefitinib.However, we could not clarify the mechanisms behind the effectiveness of erlotinib in this population. There are several potential explanations: (i) erlotinib was administered at the maximumtolerateddose,whereasgefitinibwasadministered atapproximatelyoneofthirdofitsmaximumtolerateddose. Thestandarddosesoferlotinibandgefitinibarenotbiologicallyequivalent.(ii)Thedifferenceintumorsensitivitymight be associated with the relative concentration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). (iii) The IC 50 value of erlotinib is much lower than thatofgefitinib [4] .
Ontheotherhand,Asamietal.
[5]haddocumentedthat erlotinibmayachieveasurvivalbenefitforpatientswithpulmonaryadenocarcinomawithlessthan12monthsoftimeto progressiononpriorgefitinibwhoshowedaPRtogefitinib. A second biopsy was performed on the progressed lesions afterfailureofgefitinibtherapy,andincaseswithtimetoprogressionoflessthan12monthsnoEGFRT790Mmutations were found. Therefore, they suggest that tumor clones may Onkologie2012;35:8-9
ErlotinibafterFailureofGefitinibinNSCLC 9 erlotinibafterfailureofgefitinibhavebeenpublished,however,9areretrospectiveandonly3prospective.Toevaluate the efficacy of erlotinib as salvage treatment after failure of prior gefitinib, a large prospective study is warranted to confirmtheseobservations. In summary, the findings of Saito and colleagues demonstratetheclinicalefficacyoferlotinibinNSCLCpatientswith long-termSDofmorethan6monthswhilereceivinggefitinib. This retrospective study has a small sample size which may give rise to selection bias. Out of the NSCLC patients with significant benefit from prior gefitinib therapy, some may benefit from erlotinib as salvage treatment. Little is known about the detailed mechanisms of efficacy of erlotinib after failure of gefitinib. A significant (6 months) clinical benefit (SD)afterinitiationofEGFR-TKIshasbeendescribedtobe one of the factors for acquired resistance to EGFR-TKIs in NSCLC,therefore,wedonotrecommendtoroutinelyadministererlotinibtoNSCLCpatientswithlong-termSDofmore than6monthsaftergefitinibtreatment.
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